New combo pill for diabetes tested in thousands of patients

NCT ID NCT07023172

Recruiting now Disease control Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is tracking 3000 adults with type 2 diabetes who are starting a new combination pill called Proline Plus Empagliflozin. Researchers want to see how well it controls blood sugar and if it is safe when used in everyday medical practice. The study does not change how doctors treat patients—it simply observes what happens over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proline Plus Empagliflozin tablets (a combination drug to lower blood sugar)
What this could lead to: If successful, this study could confirm that Proline Plus Empagliflozin works well in everyday practice for managing type 2 diabetes.
What could go wrong: This is an observational study, not a controlled trial, so results may be less reliable. It is also only for people already prescribed the drug, limiting generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 2 DIABETES

Contacts and locations

Locations

Affiliated Drum Tower Hospital, Medical School of Nanjing University
RECRUITING

Nanjing, Jiangsu, 210000, China
Xinyang Central Hospital
RECRUITING

Xinyang, Henan, 464000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.